NTRBW 1.05 Nutriband Inc.
| Range: | 0.189-3.44 | Vol Avg: | 1306 | Last Div: | 0 | Changes: | -0.19 |
| Beta: | 0.42 | Cap: | 0.09B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 01 2021 | Empoloyees: | 3 | ||
| CUSIP: | 67092M125 | CIK: | 0001676047 | ISIN: | US67092M1255 | Country: | US |
| CEO: | Mr. Gareth Sheridan | Website: | https://nutriband.com | ||||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Stock Details
Positive 0.36
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a...
accesswire.com·Wed Oct 02 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow